<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00900055</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00000823</org_study_id>
    <secondary_id>P30CA069533</secondary_id>
    <secondary_id>OHSU-HEM-98030-L</secondary_id>
    <nct_id>NCT00900055</nct_id>
  </id_info>
  <brief_title>Research Study in Healthy Volunteers of Patients With Fanconi Anemia, Myeloproliferative Disorders, or Myeloma</brief_title>
  <official_title>Dysregulation of Hematopoiesis in Fanconi Anemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>OHSU Knight Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>OHSU Knight Cancer Institute</source>
  <brief_summary>
    <textblock>
      RATIONALE: Analyzing tissue and blood samples from healthy volunteers or patients with
      Fanconi anemia, myelodysplasia, myeloproliferative disorders, or myeloma in the laboratory
      may help doctors learn more about the causes of blood cancers.

      PURPOSE: The purpose of this study is to analyze in the laboratory blood and bone marrow
      cells from healthy volunteers or patients with Fanconi anemia, myeloproliferative disorders,
      or myeloma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Identify the specific molecular function of the Fanconi anemia (FA) complementing gene
           products in hematopoietic progenitor cells from patients and normal volunteers.

        -  Identify functional defects in hematopoietic stromal cells, including macrophages, from
           patients with FA, and selected blood cancers as well as normal volunteers.

      OUTLINE: Peripheral blood mononuclear leukocytes, skin fibroblasts, and marrow fibroblasts
      are collected for loss-of-function and gain-of-function analysis related to the Fanconi
      anemia complementing gene.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>June 1975</start_date>
  <completion_date type="Anticipated">January 2020</completion_date>
  <primary_completion_date type="Anticipated">January 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Loss of function analyses</measure>
    <time_frame>Duration of the study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proteins binding to Fanconi anemia, complementation group C (FACC) gene-product by affinity chromatography of nuclear and whole cell lysates of normal cells</measure>
    <time_frame>Duration of the study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Screening of proteins binding to FACC gene-product using monoclonal antibodies specific to signal transduction and cell cycle proteins</measure>
    <time_frame>Duration of the study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Microsequencing of unique proteins</measure>
    <time_frame>Duration of the study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Location of specific downstream block point imposed by antisense molecules using antibodies specific to signal transduction, cell cycle, or repair proteins for the FACC protein</measure>
    <time_frame>Duration of the study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Affirmation that the block points identified are recapitulated in progenitor cells from peripheral blood</measure>
    <time_frame>Duration of the study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Identification of functional defects in Fanconi anemia hematopoietic stromal cells</measure>
    <time_frame>Duration of the study</time_frame>
  </primary_outcome>
  <enrollment type="Actual">213</enrollment>
  <condition>Chronic Myeloproliferative Disorders</condition>
  <condition>Fanconi Anemia</condition>
  <condition>Multiple Myeloma and Plasma Cell Neoplasm</condition>
  <condition>Myelodysplastic/Myeloproliferative Neoplasms</condition>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>microarray analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>polyacrylamide gel electrophoresis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>polymerase chain reaction</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>protein expression analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>reverse transcriptase-polymerase chain reaction</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>western blotting</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>chromatography</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>high performance liquid chromatography</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>immunoenzyme technique</intervention_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The Center for Hematologic Malignancies, the Knight Cancer Institute at OHSU, and the Bone
        Marrow Failure clinic at Doernbecher Children's Hospital at OHSU will be centers for
        recruitment.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Meets 1 of the following criteria:

               -  Diagnosis of one of the following:

                    -  Fanconi's anemia requiring bone marrow biopsy as part of standard care
                       (adults and children)

                    -  Myeloproliferative disorder or myeloma (adults)

               -  Healthy volunteer, meeting 1 of the following criteria:

                    -  Over 18 years of age

                    -  Bone marrow transplant donor (children)

        PATIENT CHARACTERISTICS:

          -  Hemoglobin &gt; 13 g/dL

          -  White blood cells (WBC) &gt; 4,000/mm³

          -  Platelet count &gt; 150,000/mm³

          -  No clinical signs or symptoms of acute or subacute infections (viral, bacterial, or
             fungal)

          -  No known blood abnormality (healthy volunteers)

          -  No allergies to lidocaine or xylocaine

        PRIOR CONCURRENT THERAPY:

          -  Not specified
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Grover C. Bagby, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>OHSU Knight Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Knight Cancer Institute at Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239-3098</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 9, 2009</study_first_submitted>
  <study_first_submitted_qc>May 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2009</study_first_posted>
  <last_update_submitted>January 8, 2018</last_update_submitted>
  <last_update_submitted_qc>January 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>OHSU Knight Cancer Institute</investigator_affiliation>
    <investigator_full_name>Laura Newell</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Fanconi anemia</keyword>
  <keyword>multiple myeloma and other plasma cell neoplasms</keyword>
  <keyword>chronic myeloproliferative disorders</keyword>
  <keyword>myelodysplastic/myeloproliferative neoplasms</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
    <mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
    <mesh_term>Fanconi Anemia</mesh_term>
    <mesh_term>Fanconi Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

